Biocryst Pharmaceuticals (BCRX) Profit After Tax Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | -303.53% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -17.27% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 34.32% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.12 Bn | 214.41 Mn | 1,300.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,300.16% |
| Mar 31, 2026 | -297,141.98% |
| Dec 31, 2025 | 79.06% |
| Sep 30, 2025 | 191.92% |
| Jun 30, 2025 | 140.12% |
| Mar 31, 2025 | 142.93% |
| Dec 31, 2024 | -46.20% |
| Sep 30, 2024 | 61.06% |
| Jun 30, 2024 | 83.17% |
| Mar 31, 2024 | 98.94% |
| Dec 31, 2023 | 13.38% |
| Sep 30, 2023 | 15.24% |
| Jun 30, 2023 | -27.98% |
| Mar 31, 2023 | 28.12% |
| Dec 31, 2022 | -304.81% |
| Sep 30, 2022 | 27.66% |
| Jun 30, 2022 | -36.25% |
| Mar 31, 2022 | -15.42% |
| Dec 31, 2021 | 70.90% |
| Sep 30, 2021 | -27.47% |